ArticleQatar medical journal2025
The impact of the COVID-19 Pandemic on breast cancer incidence and stage: Results of a retrospective study.
Article in Qatar medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The study was conducted to determine the impact of the COVID-19 pandemic on the incidence and stage of breast cancer in different age groups. Methods: This retrospective study analyzed changes in the epidemiological and clinical structure of the cohort of patients treated in the radiotherapy department of the Bydgoszcz Oncology Centre in Poland from 2016 to 2023. Results: The results of the study showed that in the group of patients under 39 years of age, an increase in the incidence rate was recorded in 2020, and a decrease in 2021 to 2023. A decrease in the incidence rate was also observed in the group of patients aged 40 to 49 years in the period 2021 to 2022 and in the groups 50 to 59, 60 to 69, and >80, from 2020 to 2023. An increase in the incidence rate was recorded in the group of patients aged 70 to 79 years in 2020, 2022, and 2023, and a decrease was observed in 2021. In the group of patients under 40 years of age, the impact of the pandemic on reducing the number of cases of stage I cancer was recorded in 2020, 2022, 2023, stage IIa-in 2020, stage IIIa-from 2020 to 2023, stage IIIb-in 2020. Instead, in 2020, the number of cases of stage IIb and stage IIIc breast cancer increased, and the rate of stage IV cancer detection increased significantly, which remained high throughout the pandemic. In the group of patients over 40 years of age, a decrease in the detection rate of stage I cancer was observed from 2020 to 2023, and stage IIa in 2020. An increase in stage IIIa cancer detection was recorded in 2020, stage IIIb in 2021 to 2023, and a significant increase in stage IV detection from 2020 to 2023. Conclusion: The results demonstrated that the COVID-19 pandemic has become one of the important factors in the delayed diagnosis of breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.